Funding for this research was provided by:
Beijing Hope Run Special Fund of the Cancer Foundation of China (LC2014L12)
The National Key Projects of Research and Development of China (2016YFC0904600, 2017YFC0107500)
Received: 12 May 2019
Accepted: 22 November 2019
First Online: 12 December 2019
Ethics approval and consent to participate
: This is re-analysis of a phase 3 clinical study. The prospective study was approved by National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College (No.CAMSCHRTOG2002–1) Institutional Review Board. All patients provided written informed consent prior to treatment, and all information was anonymized prior to analysis.
: Not applicable.
: The authors declare that they have no competing interests.